Lecanemab, which will be available under the name Leqembi, can slow the cognitive decline associated with Alzheimer’s disease ...

Researchers have developed a novel compound that could transform the way we treat Alzheimer's disease, offering not just a ...

Add Yahoo as a preferred source to see more of our stories on Google. Lecanemab is the first novel treatment for Alzheimer's in more than 20 years Lecanemab, the disease-modifying drug which can slow ...

Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term TreatmentTOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ...

The research team examined data on the health status of 2,672 patients 28 weeks after the start of the treatment.

Please provide your email address to receive an email when new articles are posted on . Lecanemab led to more infusion reactions than in CLARITY-AD clinical trial. Patients had lower ARIA rates in ...

BioArctic's AB (publ) (NASDAQ: BIOA B) partner Eisai presented new data at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™), held ...

The experimental drug lecanemab shows "potential" as an Alzheimer's disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Lecanemab led to a 44% reduction of biomarker ...

A "boot camp" session at the American Academy of Neurology (AAN) annual meeting focused on the logistical challenges of prescribing lecanemab (Leqembi) for Alzheimer's disease, including how to select ...

Scientists at the University of Kentucky have uncovered a biological signal that may help explain one of the most concerning ...